Articles tagged "Viral therapy"

2021 American Transplant Congress
Real-world Treatment Patterns of Antiviral Agents for Cytomegalovirus Among Adult Kidney Transplant Recipients: A USRDS-Medicare Linked Database Study
A. D. Raval¹, M. Ganz², P. Saravanan², Y. Tang¹, C. A. Santos³
¹Merck & Co., Inc., Kenilworth, NJ, ²Evidera, Inc., Waltham, MA, ³Rush University Medical Center, Chicago, IL
*Purpose: Cytomegalovirus (CMV) is a common viral pathogen among kidney transplant recipients (KTRs). Although guidelines recommend the use of prophylaxis or pre-emptive antiviral (AV) therapy…
2021 American Transplant Congress
Impact of Cytomegalovirus Prophylaxis on Herpes Simplex and Varicella Zoster Virus Infections in Kidney Transplant Recipients
K. Ridgely¹, B. Crowther², P. Klem², K. Schoeppler¹, K. Schwarz¹, A. Nadrash², V. Lewis¹, E. Benamu³
¹Department of Pharmacy Services, UCHealth University of Colorado Hospital, Aurora, CO, ²Ambulatory Care Pharmacy Services, UCHealth University of Colorado Hospital, Aurora, CO, ³Department of Medicine, UCHealth University of Colorado Hospital, Aurora, CO
*Purpose: To assess the impact of cytomegalovirus (CMV) targeted antiviral prophylaxis on the development of herpes simplex (HSV) and varicella zoster (VZV) infections after kidney…
2021 American Transplant Congress
Clinical Outcomes of Solid Organ Transplant Recipients Treated with Remdesivir and Convalescent Plasma for Covid-19 at the Largest Transplant Center in the United States
A. Fernandez, S. Anjan, A. Chandorkar, D. de Lima, R. Zamora, L. A. Mendez-Castaner, J. Simkins, J. Camargo, M. Morris, M. Loebe, J. Bauerlein, C. O’Brien, N. Sinha, G. Burke, G. Ciancio, A. Mattiazzi, R. Vianna, L. Abbo, G. Guerra, Y. Natori
Miami Transplant Institute, Jackson Health System, Miami, FL
*Purpose: Solid organ transplant recipients (SOTr) are at high risk for severe disease with SARS-CoV-2. Data on efficacy of potential treatment options and long-term outcomes…
2021 American Transplant Congress
Longitudinal Antibody Response and Viral Loads in Covid-infected Organ Transplant Recipients
T. M. Marinelli, V. H. Ferreira, M. Ierullo, V. Kulasingham, B. Majchrzak-Kita, C. Rotstein, S. Husain, S. Hosseini, A. Humar, D. Kumar
UHN, Toronto, ON, Canada
*Purpose: The full spectrum of COVID-19 disease and the impact of disease severity on antibody response and viral shedding dynamics in transplant patients is unclear.…
2021 American Transplant Congress
Leflunomide Therapy for Treatment of Bk Viremia in Pediatric Kidney Transplant Recipients
A. Aldieri¹, M. Chandran², D. Matossian³, B. Magella⁴, D. Lazear⁴, M. Bock², E. Blanchette²
¹Children's Hospital Colorado, Denver, CO, ²Children's Hospital Colorado, Aurora, CO, ³Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH
*Purpose: BK viremia (BKV) after kidney transplantation (KT) poses significant risk for BK virus-associated nephropathy (BKVN) and impacts graft survival. Conventional treatment involves reduction of…
2021 American Transplant Congress
Influence of Induction Therapy and Antiretroviral Regimen on Outcomes in HIV Positive Renal Transplant Recipients
C. Rogers Marks¹, C. Durand², J. Hand³, M. Abidi⁴, M. Malinis⁵, B. Barnaba², H. Patel⁶, C. D. Alonso⁶
¹Massachussetts General Hospital, Boston, MA, ²Johns Hopkins Medical Center, Baltimore, MD, ³Ochsner Medical Center, New Orleans, LA, ⁴Univ. of Colorado, Aurora, CO, ⁵Yale, New Haven, CT, ⁶Beth Israel Deaconess Medical Center, Boston, MA
*Purpose: Transplantation of HIV+ individuals has become more common over the past decade with increasing data supporting good outcomes. Questions remain regarding the impact of…
2020 American Transplant Congress
Comparison of Prophylaxis Strategies for CMV Infection in Liver Transplant Recipients
K. Schnelle, A. Leino, M. Chunduru, L. Von Stein, O. Witkowsky
The Ohio State Wexner Medical Center, Columbus, OH
*Purpose: The best strategy to prevent cytomegalovirus (CMV) following liver transplantation is not defined for intermediate risk recipients (recipient seropositive (R+) regardless of donor status).…
2020 American Transplant Congress
Brincidofovir for Adenovirus Disease in Adult Renal Transplant Recipients: A Case Series
F. Zervou¹, I. Zacharioudakis¹, S. A. Mehta², H. J. Neumann²
¹Infectious Diseases, New York University Langone, New York, NY, ²New York University Langone Transplant Institute, New York, NY
*Purpose: Adenovirus infection can lead to disease in solid organ transplant recipients, including disease of the allograft. Treatment options for severe disease are limited. Brincidofovir…
2020 American Transplant Congress
Utilization of Organs from Donors Exposed to Hepatitis C: ? Standard of Care
M. Marvin¹, S. Gaines², P. Mohan³, A. Kotru¹, C. Koo¹, B. Addissie⁴, A. Unzueta⁴, S. Khurana⁴
¹Transplantation and Liver Surgery, Geisinger, Danville, PA, ²Pharmacy, Geisinger, Danville, PA, ³Nephrology, Geisinger, Danville, PA, ⁴Hepatology, Geisinger, Danville, PA
*Purpose: To report the results of a clinical program to utilize livers and kidneys from donors exposed to Hepatitis C.*Methods: We initially started to explore…
2020 American Transplant Congress
Viral Kinetics of De Novo HCV Infection and Response to Antiviral Therapy in Liver and Kidney Transplant Recipients Receiving HCV-Viremic Donors
N. Terrault¹, J. Burton², E. Verna³, C. Mobley⁴, D. Victor⁴, J. Trotter⁵, C. Niemann⁶, R. Rubin⁷
¹University of Southern California, Los Angeles, CA, ²UC, Denver, CO, ³Columbia Universeity, New York, NY, ⁴Houston Methodist, Houston, TX, ⁵Baylor University, Dallas, TX, ⁶UCSF, San Francisco, CA, ⁷Piedmont Atlanta Hosptial, Atlanta, GA
*Purpose: There is general agreement that expanded use of organs from HCV-viremic donors is desirable, including in recipients without HCV infection. However, the optimal treatment…